Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04167449
Other study ID # EP-1006
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 1, 2019
Est. completion date May 1, 2020

Study information

Verified date February 2021
Source EuroPharma, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, randomized, double blind, placebo-controlled study to determine if a hydroponically-cultivated red ginseng preparation is superior to conventionally grown ginseng and placebo for positively affecting electrical activity of the brain during performance of various cognitive tasks.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 1, 2020
Est. primary completion date March 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 75 Years
Eligibility Inclusion Criteria: - Subject must be capable of giving informed consent. - Acceptance of written consent to participate in the study after instruction in written and oral form (informed consent). Exclusion Criteria: - Subjects with acute or chronic diseases that are relevant to the study and asked for by the study staff are excluded: - Acute or chronic disease with an impact on the study, which becomes obvious by case history or clinical examination. - Clinically relevant allergic symptoms. - Detection of alcohol at the time of initial examination (day SC) or on any study (positive alcohol test) or by case history. - Consumption of clinically relevant medication during last 14 days before and during the active study period based on the notification of the subject or his case history. - Consumption of medication with primarily central action (i.e. psychotropic drugs or centrally acting antihypertensive drugs). Known intolerance / hypersensitivity (allergy) to plant derived extracts or any of the ingredients of the investigational product (anamnestic). - Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea (more than 4 cups a day). - Smoking in the study center on study days A, B, C and D. - Participation in another clinical trial within the last 60 days. - Bad compliance. - Cancellation of informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
HRG80 Hydroponic Red Ginseng
Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
Conventional White Ginseng
Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
Placebo
Visually identical placebo capsule containing rice flour

Locations

Country Name City State
Germany Clinical Labors of NeuroCode AG Wetzlar

Sponsors (1)

Lead Sponsor Collaborator
EuroPharma, Inc.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in baseline electrical activity of the brain as measured by Quantitative Electroencephalogram for the hydroponic Korean red ginseng preparation versus conventional ginseng and placebo Responses of electric brain activity as spectral power in 17 different brain regions within 6 specially defined frequency ranges (delta, theta, alpha1, alpha2, beta1 and beta2) during cognitive performance: d2-test for attention (d2-Test). Four weeks
Primary Change in baseline electrical activity of the brain as measured by Quantitative Electroencephalogram for the hydroponic Korean red ginseng preparation versus conventional ginseng and placebo Responses of electric brain activity as spectral power in 17 different brain regions within 6 specially defined frequency ranges (delta, theta, alpha1, alpha2, beta1 and beta2) during cognitive performance: memory test (ME-Test). Four weeks
Primary Change in baseline electrical activity of the brain as measured by Quantitative Electroencephalogram for the hydroponic Korean red ginseng preparation versus conventional ginseng and placebo Responses of electric brain activity as spectral power in 17 different brain regions within 6 specially defined frequency ranges (delta, theta, alpha1, alpha2, beta1 and beta2) during cognitive performance: concentration-performance-test with financial reward (CPT-Test). Four weeks
See also
  Status Clinical Trial Phase
Completed NCT03797274 - Quantitative EEG During Anesthesia Emergence in Children